NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel’s coverage, with a buy rating and a $44 price target.

NewAmsterdam Pharma initiated with a Buy at Stifel

A scientist in a lab coat standing in a research lab examining biopharmaceuticals.

According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core asset, obicetrapib, has the potential to differentiate itself in the growing lipid-lowering market, according to Stifel.

The analyst points out that obicetrapib potentially differs from earlier attempts in the CETP inhibitor market due to the company’s cardiovascular outcomes trial, PREVAIL. Stifel anticipates significant upside even under cautious commercial assumptions.

The CETP inhibitor obicetrapib, which is being developed by NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), is intended to decrease cholesterol in the treatment of cardiovascular disease. Stifel cites the PREVAIL study and an extensive amount of supporting data to show that obicetrapib differs significantly from previous CETP failures. New Amsterdam has a legitimate route to market access due to this distinction and impending regulatory milestones.

Stifel’s $44 price estimate shows that they are confident in the drug’s clinical uniqueness and market potential.

While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.